[AACR 2022] Translational Insights on Genomic Status and Biomarker Modulation Using OncoPanel and BioMAP Platforms
- Version:
- 21316
- File Name/Number:
- AACR
- Year:
- 2022
Trastuzumab (Herceptin®), a humanized monoclonal antibody (mAb) targeted against the ErbB2 protein, was approved by the FDA in 1998 and the EMA in 2000 to treat Her2-positive breast cancer, and in 2010 received FDA approval for the treatment of Her2-positive gastric cancer. As of April 2021 there were five biosimilars for trastuzumab with regulatory approval.